Weekly Digest – September 2026 Weekly Digest – September 2026 03 September 2026: HUTCHMED announces licensing agreement with GSK for KRAS-EGFR antibody conjugate cancer therapy HUTCHMED announced an exclusive licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy […]
Weekly Digest – September 2026 Weekly Digest – September 2026 01 September 2026: SYS6010 granted BTD by the NMPA in China for the treatment of patients with recurrent or metastatic HNSCC CSPC Pharmaceutical Group announced that SYS6010 has received Breakthrough […]
Weekly Digest – September 2026 Weekly Digest – September 2026 02 September 2026: Hansoh Pharmaceutical’s HS-20093 injection marketing authorization application for SCLC accepted by China’s NMPA Hansoh Pharma announced that the NMPA has formally accepted the marketing authorization application for […]
Weekly Digest – September 2026 Weekly Digest – September 2026 31 August 2026: IDEAYA Biosciences’ IDE849 advances to a phase 3 registrational trial following a successful FDA type C meeting for ES-SCLC IDEAYA Biosciences announced a successful FDA Type C […]
Weekly Digest – September 2026 Weekly Digest – September 2026 28 August 2026: DualityBio enters global collaboration with Roche to develop next-generation ADCs using the DUPAC novel-payload platform DualityBio announced a global collaboration and license agreement with Roche to develop […]
Weekly Digest – September 2026 Weekly Digest – September 2026 03 September 2026: HUTCHMED announces licensing agreement with GSK for KRAS-EGFR antibody conjugate cancer therapy HUTCHMED announced an exclusive licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy […]
